XML 52 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues:    
Total revenues $ 1,327,274 $ 2,829,905
Operating expenses:    
Research and development 19,111,188 24,389,888
General and administrative 7,448,354 6,975,029
Total operating expenses 26,559,542 31,364,917
Loss from operations (25,232,268) (28,535,012)
Other income (expense):    
Interest income 416,569 625,535
Interest expense (2,803,755) (656,248)
Change in fair value of derivative liability (13,221,977) 0
Gain (loss) on investment in affiliated entities 13,181,619 (750,103)
Other income (expense), net (425,500) (35,839)
Net loss before income tax benefit/(provision for income tax) (33,135,404) (29,351,667)
Income tax benefit/(provision for income taxes) 0 62,800
Net loss (33,135,404) (29,288,867)
Net loss attributable to non-controlling interest 594,350 69,605
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (32,541,054) $ (29,219,262)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders    
Basic and diluted (in dollars per share) $ (0.26) $ (0.30)
Weighted average number of common shares outstanding    
Basic and diluted (in shares) 124,623,263 97,494,968
Revenue under collaborative research and development arrangements    
Revenues:    
Total revenues $ 71,500 $ 2,770,712
Revenue under collaborative research and development arrangements with affiliated entities    
Revenues:    
Total revenues 1,172,126 55,579
Miscellaneous revenue    
Revenues:    
Total revenues $ 83,648 $ 3,614